Navigation Links
d’Oliveira & Associates Seeks Clients That Have Been Affected by the Prescription Drug Topamax
Date:3/23/2013

(PRWEB) March 23, 2013

Topamax is a popular anticonvulsant prescription drug manufactured by the Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical. Originally approved by The U.S. Food and Drug Administration (FDA) in 1996 to treat persons experiencing epileptic seizures, the drug has since been approved as an anti-migraine drug and has thus become a popular drug for both combating epileptic seizures and migraines*. In just 2007 to 2010 alone, nearly 4.3 million patients filled prescriptions to Topamax*. However, in March 2011, the FDA warned that pregnant users of Topamax are at an increased risk that their children will develop birth defects as a result of the drug use*.

Specifically, the FDA's recent study into Topamax revealed that pregnant woman using the migraine and seizure drug exposed their children to an increased risk of developing cleft lip and cleft palate*. Cleft lip is a birth defect where the infant lacks the tissue needed to correctly form the upper lip during pregnancy and results in vertical gaps remaining in the child's lip. Similarly, cleft palate is a birth defect where the child is left with gaps in the back portions and sides of the mouth due to a lack of tissue required for formation during the pregnancy. Both conditions put the child at risk for chronic hearing loss, eating and drinking problems, speech development problems, and even poor overall growth.

In its warning, the FDA has cited a recent study by The Northern American Antiepileptic Drug Pregnancy Registry, which concluded that infants exposed to Topamax (topiramate) during pregnancy are three times more at risk of developing these defects than infants exposed to competing seizure and migraine drugs. According to the study, only 0.38% of infants exposed to other various medications developed the birth defects, whereas 1.4% of the infants exposed specifically to Topamax developed them*. It is important to note that in this study, the percentage of these birth defects in infants whose mothers were exposed to no anticonvulsant medications at all was a mere .07% and that the rate of cleft lip and cleft palate conditions found in infants who mothers took Tapomax was 11 times higher than the national average of children born with those conditions*.

In response to the increased risk of birth defects in pregnant Topamax users, the FDA has called for stronger warnings on the drug's labels and has also changed the drug's pregnancy warning to a Category D, meaning there is positive evidence that the drug poses risks to infants. Director of the FDA's Division of Neurology Products has urged doctors to "carefully consider the benefits and risks of [Topamax] when prescribing it to women of child-bearing age," and to consider "alternative medications" as a preferable option to Topamax.

If you or anyone you know has taken Topamax during a pregnancy, the attorneys at d'Oliveira & Associates urge you to contact them immediately. Working with some of the leading dangerous drug lawyers handling these cases, they want you to know that pregnant users of Topamax are entitled to representation and compensation for any related birth defects.

For a free legal consultation, call 1-800-992-6878 or visit their website at dmlaw.com.

Source:

Read the full story at http://www.prweb.com/releases/2013/3/prweb10548517.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d’Oliveira & Associates Issues Webpage With Current Information On Stryker Hip Implant Lawsuits
2. d’Oliveira & Associates Releases Webpage With Current Information on Fresenius Lawsuits
3. d’Oliveira & Associates Releases Mirena IUD Infographic Describing Bayer’s Deceptive Mirena Simple Style Campaign
4. d’Oliveira & Associates Issues Webpage With Current Information On Mirena IUD Lawsuits
5. d’Oliveira & Associates Releases New Webpage on Pradaxa Lawsuits
6. D’Oliveira & Associates Helps Woonsocket, RI Man Receive Over $38,000 in Back Due Benefits
7. Research shows efficacy of treatment model developed at Women & Infants
8. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
9. Vendors in Nevada, Michigan, & Illinois to be Featured on the PartyPOP.com Online Network
10. Beef & Pork Wholesaling in the US Industry Market Research Report Now Available from IBISWorld
11. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... that we have been designated as a Cigna Infertility Center of Excellence. The ... performance standards. , “It’s an honor to be designated a Cigna Infertility ...
(Date:11/30/2016)... Gardens, FL (PRWEB) , ... November 30, 2016 ... ... eating disorder and mental health treatment has announced the opening of a new ... specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both males ...
(Date:11/30/2016)... Austin, TX (PRWEB) , ... November 30, 2016 ... ... like to remind the clinical research community that the FDA Binding Guidance goes ... submit data in FDA-supported formats listed in the FDA Data Standards Catalog. The ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... Dec. 2, 2016 CVS Health Corporation (NYSE: ... Day in New York City on Thursday, December 15, 2016, beginning at 8:00 ... team will provide an in-depth review of the company,s ... The company will also discuss 2017 earnings guidance during ... of the event will be broadcast simultaneously on the ...
(Date:12/2/2016)... YORK , December 2, 2016 ... the trading session in red, while the Dow Jones Industrial ... at the close of US markets, which prompted Stock-callers this ... stocks: NuVasive Inc. (NASDAQ: NUVA ), Smith & ... (NASDAQ: NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology: